Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections, Tuberculosis
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after…
- Trial name
- NCT00476853
- Testing
- HAART containing nevirapine
- Where
- 6 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infections
Evaluation of HIV-1 Recent Infection Testing in Rwanda
The study is a longitudinal, observational cohort study of people who are newly-diagnosed with HIV who consent to recency testing and participate in index testing services, and their disclosed contacts.
- Trial name
- NCT05063487
- Testing
- Return of recent classification, Return of long-term classification
- Where
- Rwanda
- Volunteers
- 1,588 people
- Sponsor
- Columbia University
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
HIV Infection
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.
- Trial name
- NCT00326716
- Testing
- Atazanavir + Ritonavir + Combivir
- Where
- 6 sites in United States, Puerto Rico and 1 more
- Volunteers
- 69 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Lipopeptide Immunisation With GTU-multiHIV Trial
The combination of GTU-MultiHIV B DNA and LIPO-5 vaccines in a prime-boost strategy is expected to induce strong and diverse HIV-specific immune responses in HIV-infected patients.
- Trial name
- NCT01492985
- Testing
- GTU-multHIV B vaccine and LIPO-5 vaccine
- Where
- France
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency…
- Trial name
- NCT04564547
- Testing
- Islatravir, Ulonivirine, BIC/FTC/TAF
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
HIV Infections
Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants
This study evaluated the safety and immune response in healthy HIV-exposed and uninfected infants to the protein vaccine, CH505TF gp120, adjuvanted with GLA-SE.
- Trial name
- HVTN 135 (NCT04607408)
- Testing
- CH505TF gp120, GLA-SE adjuvant
- Where
- South Africa
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections
Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents
Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study evaluated the pharmacokinetics (PK), safety, tolerability of and immune response to DTG when used concurrently with optimized background therapy…
- Trial name
- NCT01302847
- Testing
- DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets
- Where
- 33 sites in United States, Botswana and 6 more
- Volunteers
- 181 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Renal Integrase Study
The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir), when…
- Trial name
- NCT02351908
- Testing
- Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- St Stephens Aids Trust
HIV-1-infection
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE
This study will evaluate the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected patients who actively use illicit substances.
- Trial name
- BASE (NCT03998176)
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Nebraska
HIV, Brain Tumors
Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments
Background: People with chronic illness often are at risk for developing neurobehavioral problems due to effects of the disease or associated treatments.
- Conditions
- HIV, Brain Tumors, Neurofibromatosis Type 1
- Trial name
- NCT01445314
- Where
- United States
- Volunteers
- 598 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
- Trial name
- NCT00002416
- Testing
- Emtricitabine, Lamivudine
- Where
- 2 sites in United States
- Volunteers
- 390 people
- Sponsor
- Triangle Pharmaceuticals
HIV-1-infection
Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption
Natural HIV controllers (HICs) and post-treatment controllers (PTCs) are rare examples of people living with HIV (PLWH) who achieve control of HIV replication without the need for antiretroviral therapy (ART).
- Trial name
- NCT07081763
- Testing
- Baricitinib 2 MG, Sirolimus 2 MG
- Volunteers
- 191 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV/AIDS, TB - Tuberculosis
Xpert Ultra and Xpert HIV-VL in People Living With HIV
TB is increasingly diagnosed using the GeneXpert platform, which can be used for a variety of tests (not just TB). HIV viral load monitoring is required at least annually in patients on ART to detect failure of virologic…
- Conditions
- HIV/AIDS, TB - Tuberculosis, Antiretroviral Therapy, Highly Active
- Trial name
- NCT03187964
- Testing
- PLHIV Point of Care Xpert Ultra, PLHIV Point of Care Xpert VL
- Where
- South Africa
- Volunteers
- 1,053 people
- Sponsor
- University of Stellenbosch
HIV-1 Infection, Chronic Renal Insufficiency
Renal Transplantation and Raltegravir in HIV-Infected Patients
The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
- Trial name
- ANRS153TREVE (NCT01453192)
- Testing
- Raltegravir
- Where
- 14 sites in France
- Volunteers
- 27 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Targeting Platelets in Chronic HIV Infection
Advances in antiretroviral therapy (ART) have resulted in increased survival of the HIV-infected population; however, this gain in longevity is associated with an increased risk of cardiovascular disease (CVD).
- Trial name
- NCT02578706
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV Infections
A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil once a day for 4 weeks to HIV-infected patients who never have been treated with anti-HIV medicine.
- Trial name
- NCT00002206
- Testing
- Adefovir dipivoxil
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gilead Sciences
HIV Infections
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not.
- Trial name
- NCT00074581
- Testing
- Atazanavir, Didanosine, Efavirenz
- Where
- 17 sites in United States, Botswana and 7 more
- Volunteers
- 3,526 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immune Deficiency Syndrome Virus
Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and…
- Trial name
- NCT02337322
- Testing
- Dolutegravir, Darunavir/r
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Juan A. Arnaiz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.